Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › VYGR

Voyager Therapeutics

VYGR Rare disease Lead: Phase 1 9 Biotech Distilled articles ↓ 26 filings & releases ↓ Cash $48.4M (Sep 30, 2026) ↓ 9 verdicts ↓ 8 timing quotes ↓
MetabolicNeurology Gene TherapyProteinSmall Molecule

Market cap $116M 62.2M shares (10-Q, Oct 30, 2026) × $1.87 close Nov 6, 2026

Most recent annual filing: 2026-03-09

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. VY7523 interim4Q 2026VY7523 interim, 4Q 2026, major
  2. VY1706 trial start4Q 2026VY1706 trial start, 4Q 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (9 active programs)

Technology platforms

TRACER

Tropism Redirection of AAV by Cell-type-specific Expression of RNA — RNA-based AAV capsid discovery platform enabling rapid discovery of capsids with robust BBB penetration and enhanced CNS tropism in multiple species including NHPs; used to generate novel capsids for intravenously delivered AAV gene therapies targeting neurological diseases including Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, SMA, and Huntington's disease.

Targets: ALPL, ApoE4, ApoE2

Voyager NeuroShuttle

Non-viral delivery platform leveraging novel receptor-binding molecules (initially ALPL receptor) to transport multiple modalities of neurotherapeutics across the blood-brain barrier; early discovery stage targeting undisclosed neurological disease; demonstrated sustained brain expression over three weeks in murine proof-of-concept studies.

Targets: ALPL, TfR

Capital (as filed)

Cash
$48.4M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$58.4M Sep 30, 2026
Long-term investments
$25.3M Sep 30, 2026
Operating cash flow
−$19.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$132M cash, runway Q2 2028 per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (9)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (9 calls)

Every verdict Biotech Distilled has published on Voyager Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-03-17 Watch Voyager Therapeutics (VYGR) - Scientific Deep Dive for Lead and Pipeline Products Voyager is a high-value delivery platform with compelling NHP data but binary H2 2026 clinical risk; smart money should wait for Biogen's BIIB080 Phase 2 readout before deploying capital.
  2. 2026-04-27 Watch UPDATE: Voyager Therapeutics (VYGR) - The Second C-Suite Exit and the 240M-Share Tell Two C-suite exits in 70 days plus a proxy request to double authorized shares deepens the bear case; the proxy waiting game is the right call with dilution risk now actively widening.
  3. 2026-05-08 Watch UPDATE: Voyager Therapeutics (VYGR) - The Q1 Print Answers Two Open Questions Q1 GLP tox confirmed on schedule and Type C FDA meeting completed are positive process signals, but the ATM is now live and dilution risk is real; the proxy waiting game continues with a slightly cleaner edge.
  4. 2026-05-14 Watch UPDATE: Voyager Therapeutics (VYGR) - The AAV Liver Ghost Got Quieter Clean 3-month NHP tox at top dose and reproduced tau knockdown efficacy incrementally de-risk the AAV liver toxicity sell trigger, but Biogen readout and FIH dosing still own the directional decision.
  5. 2026-05-16 Watch UPDATE: Voyager Therapeutics (VYGR) - EcoR1 Walks EcoR1's full exit filing two days after the ASGCT preclinical win narrows the institutional support base heading into the catalyst window, walking back the incremental bull lean.
  6. 2026-06-02 Watch UPDATE: Voyager Therapeutics (VYGR) - The IND Lands FDA clearance of the VY1706 IND on schedule with a dose ceiling preserving the 4x NHP safety margin is a real execution receipt, but Biogen readout and FIH dosing still own the directional decision.
  7. 2026-06-10 Watch UPDATE: Voyager Therapeutics (VYGR) - The War-Chest Vote Passes 240M authorized shares approved 99.4% makes dilution authority structural; at $3.32 a fully-drawn ATM equals ~48% of shares outstanding, confirming the toxic dilution scenario while the Biogen readout remains the key catalyst.
  8. 2026-08-07 Watch UPDATE: Voyager Therapeutics (VYGR) - The Catalysts Slide Into Q4 Both Alzheimer's catalysts pushed to Q4 2026 and VY1706 first human safety data slipped to early 2027, while the ATM is being tapped into weakness at ~$3.61; the proxy waiting game got longer.
  9. 2026-10-22 Watch UPDATE: Voyager Therapeutics (VYGR) - The Scientist Hands Over the Keys CEO and acting CMO departing after the safety readout with CMO and CFO seats still unfilled creates a leadership gap through the clinical translation window; below-cash valuation and two near-term catalysts justify only a small option-like position if held at all.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (8 quotes from 5 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (26)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)